{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:28:06Z","timestamp":1790962086670,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ijcard.2018.07.138","type":"journal-article","created":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T02:14:19Z","timestamp":1532830459000},"page":"152-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study"],"prefix":"10.1016","volume":"269","author":[{"given":"Maria Cristina","family":"Vedovati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Giustozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verdecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pierpaoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serenella","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Verso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-9908","authenticated-orcid":false,"given":"Emanuela","family":"Marchesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bogliari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ijcard.2018.07.138_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4330\/wjc.v5.i7.215","article-title":"Atrial fibrillation in heart failure: the sword of Damocles revisited","volume":"5","author":"Khan","year":"2013","journal-title":"World J. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2018.07.138_bb0010","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2018.07.138_bb0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.STR.28.2.316","article-title":"Atrial fibrillation and dementia in a population-based study. The Rotterdam study","volume":"28","author":"Ott","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.07.138_bb0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2016.06.009","article-title":"Pathophysiology of cancer therapy-provoked atrial fibrillation","volume":"219","author":"Cheng","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2018.07.138_bb0025","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2018.07.138_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","article-title":"Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry","volume":"3","author":"Melloni","year":"2017","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"issue":"6","key":"10.1016\/j.ijcard.2018.07.138_bb0035","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.ijcard.2018.07.138_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.ijcard.2018.07.138_bb0045","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am. J. Med."},{"issue":"Suppl. 11","key":"10.1016\/j.ijcard.2018.07.138_bb0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(17)33714-2","article-title":"Efficacy and safety of edoxaban in patients with atrial fibrillation and active malignancy: an analysis of ENGAGE AF-TIMI 48 randomized clinical trial","volume":"69","author":"Fanola","year":"2017","journal-title":"JACC"},{"issue":"11","key":"10.1016\/j.ijcard.2018.07.138_bb0055","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.ijcard.2018.07.138_bb0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.ijcard.2018.07.138_bb0065","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ijcard.2018.07.138_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.ijcard.2018.07.138_bb0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.amjcard.2017.04.009","article-title":"Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer","volume":"120","author":"Laube","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2018.07.138_bb0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0038-1648229","article-title":"Anticancer drug-related nonvalvular atrial fibrillation: challenges in management and antithrombotic strategies","volume":"44","author":"Tufano","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2018.07.138_bb0085","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","article-title":"Bleeding complications during anticoagulant treatment in patients with cancer","volume":"133","author":"Kamphuisen","year":"2014","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.ijcard.2018.07.138_bb0090","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation","volume":"120","author":"Patell","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2018.07.138_bb0095","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjcard.2017.11.027","article-title":"In-hospital cerebrovascular outcomes of patients with atrial fibrillation and cancer (from the national inpatient sample database)","volume":"121","author":"Elbadawi","year":"2018","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2018.07.138_bb0100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"D'Souza","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2018.07.138_bb0105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/2047487318766942","article-title":"To teach an old dog new tricks: the limits of CHA(2)DS(2)-VASc in patients with atrial fibrillation and cancer","volume":"25","author":"Yao","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2018.07.138_bb0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4070\/kcj.2017.0328","article-title":"Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer","volume":"48","author":"Kim","year":"2018","journal-title":"Kor. Circ. J."},{"issue":"3","key":"10.1016\/j.ijcard.2018.07.138_bb0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.ijcard.2018.07.138_bb0120","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijcard.2018.07.138_bb0125","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318327190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318327190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T17:20:42Z","timestamp":1541006442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318327190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"alternative-id":["S0167527318327190"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.07.138","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.07.138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}